Bloomberg Podcasts
@bloombergpodcasts·503K subscribers·32.4K videos
Compass Pathways Eyes FDA Approval for Psilocybin Depression Drug
Posted
December 4, 2025
Views
3,493
Likes
39
Comments
5
Engagement
December 4, 2025
3,493
39
5
1.26%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
7:35Now PlayingEncouraging trial data is instilling both confidence and capital back into the psychedelic drug market, with estimates suggesting growth up towards $7 billion by the year 2032. One pharmaceutical company, Compass Pathways, has begun final stage studies aimed at using psilocybin for the treatment of patients with depression. CEO Kabir Nath joined Carol Massar and Alexis Christoforous on 'Bloomberg Businessweek Daily' to discuss commercial viability for psilocybin and the future of the psychedelic drug development market.
--------
Watch Bloomberg Radio LIVE on YouTube
Weekdays 7am-6pm ET
Follow us on X
Subscribe to our Podcasts:
Bloomberg Daybreak
Bloomberg Surveillance
Bloomberg Intelligence
Balance of Power
Bloomberg Businessweek
Listen on Apple CarPlay and Android Auto with the Bloomberg Business app:
Apple CarPlay
Android Auto
Visit our YouTube channels:
Bloomberg Podcasts
Bloomberg Television
Bloomberg Originals
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
